53.47
0.38 (0.72%)
| Previous Close | 53.09 |
| Open | 53.09 |
| Volume | 679,059 |
| Avg. Volume (3M) | 966,490 |
| Market Cap | 5,397,903,360 |
| Price / Book | 14.72 |
| 52 Weeks Range | |
| Earnings Date | 3 Aug 2023 - 7 Aug 2023 |
| Diluted EPS (TTM) | -9.37 |
| Total Debt/Equity (MRQ) | 8.01% |
| Current Ratio (MRQ) | 2.89 |
| Operating Cash Flow (TTM) | -526.59 M |
| Levered Free Cash Flow (TTM) | -397.26 M |
| Return on Assets (TTM) | -118.79% |
| Return on Equity (TTM) | -265.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Biohaven Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.16% |
| % Held by Institutions | 86.77% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Jun 2024 | 5,199,219 |
| Bellevue Group Ag | 30 Jun 2024 | 2,040,853 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 76.00 (Piper Sandler, 42.14%) | Buy |
| Median | 61.00 (14.08%) | |
| Low | 57.00 (Jefferies, 6.60%) | Buy |
| Average | 64.10 (19.88%) | |
| Total | 10 Buy | |
| Avg. Price @ Call | 45.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Nov 2024 | 59.00 (10.34%) | Buy | 47.28 |
| 14 Nov 2024 | 59.00 (10.34%) | Buy | 48.66 | |
| RBC Capital | 25 Nov 2024 | 58.00 (8.47%) | Buy | 45.23 |
| 13 Nov 2024 | 66.00 (23.43%) | Buy | 49.04 | |
| TD Cowen | 13 Nov 2024 | 75.00 (40.27%) | Buy | 49.04 |
| JP Morgan | 03 Oct 2024 | 68.00 (27.17%) | Buy | 46.65 |
| B of A Securities | 24 Sep 2024 | 62.00 (15.95%) | Buy | 45.04 |
| Bernstein | 24 Sep 2024 | 66.00 (23.43%) | Buy | 45.04 |
| 04 Sep 2024 | 55.00 (2.86%) | Buy | 37.85 | |
| Baird | 23 Sep 2024 | 60.00 (12.21%) | Buy | 45.94 |
| Leerink Partners | 23 Sep 2024 | 60.00 (12.21%) | Buy | 45.94 |
| Piper Sandler | 23 Sep 2024 | 76.00 (42.14%) | Buy | 45.94 |
| Jefferies | 16 Sep 2024 | 57.00 (6.60%) | Buy | 39.02 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Nov 2024 | Announcement | Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity |
| 12 Nov 2024 | Announcement | Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments |
| 02 Oct 2024 | Announcement | Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares |
| 01 Oct 2024 | Announcement | Biohaven Announces Pricing of $250 Million Public Offering of Common Shares |
| 30 Sep 2024 | Announcement | Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine |
| 30 Sep 2024 | Announcement | Biohaven Announces Proposed Public Offering of Common Shares |
| 23 Sep 2024 | Announcement | Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) |
| 20 Sep 2024 | Announcement | Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |